Sales & Marketing Execution drift: Why pharmaceutical go-to-market falls short... Execution drift occurs when strategy, targeting, metrics, incentives, and behaviour gradually stop reinforcing one another.
R&D Rare disease at an inflection point: Why the next wave will ... As rare disease becomes more competitive, information parity is disappearing.
News MSD splits pharma business, hiving off oncology MSD is separating its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31bn blockbuster Keytruda.
News JPM: Novo Nordisk CEO gives insight into new strategy Novo Nordisk CEO Mike Doustdar covers oral Wegovy, DTC sales channels, and an under-appreciated obesity pipeline in a wide-ranging presentation.
Digital From weeks to minutes: How AI transforms pharmaceutical mark... Agentic AI isn’t just another analytical instrument. It represents a reimagining of how strategic intelligence is generated and applied.
Sales & Marketing Sponsored Beyond the launch date: Why pharma must rethink readiness fo... Explore why pharma companies must rethink their NHS strategies post-launch, with tools like IQVIA'S Market Access Launch Pad.
News Kidney biotech R1's $78m debut, and other biofinancings Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.